Product Data Sheet

Product Name: Tebentafusp
Cat. No.: GC70004

Chemical Properties

Cas. No.	1874157-95-5		
Formula		M.Wt	
Solubility		Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Tebentafusp		

Background

Tebentafusp (IMCgp100) is a bispecific fusion protein to target **gp100** peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill **gp100**-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells[1][2].

Tebentafusp □□□□□□ HLA-A*0201 □□□□□□□□□□□□ gp100 □□□□□ImmTAC[3]□
Tebentafusp (31 pM, 82 pM □131 pM; 16 h) □□ PBMC □ Mel526 □□□□□ gp100 □□ A375 □□□ □□□□□□□□□[3]□

Tebentafusp (100 pM; 0-50h) □□ $CD8^+$ T □□ (□□□□□□□ T □□) □□□□□□□40-48□□□ caspase 3/7 □□□[3]□

Tebentafusp (100 pM; 0-80 h) □□ $CD4^+$ T □□□□□□□□□□□□□□□□[3]□

Tebentafusp (1, 12, 31, 82 □131 pM; 24 h □ 96 h) □□□□□ B □□□□□□□ $CD4^+$ □ $CD8^+$ □□□□□□ □□□□□□□□□[3]□

Tebentafusp (10 μg/kg; □□□□) □□□□□□□□□□□□□□□□□[4]□

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[1]. Middleton MR, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878.
[2]. Dhillon S. Tebentafusp: First Approval. Drugs. 2022 Apr;82(6):703-710.
[3]. Boudousquie C, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology. 2017 Nov;152(3):425-438.
[4]. Baeuerle P A, et al. Passive immunotherapy by T cell-engaging bispecifi c antibodies[M]//Cancer Vaccines. CRC Press, 2015: 266-278.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA